Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and immunogenicity of the 20vPnC vaccine in infants in India and Taiwan has completed, describing safety profile and immune …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED